# Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

> **NCT03037645** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sunesis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoplasmacytoid Lymphoma
- Mantle-Cell Lymphoma
- Waldenstrom Macroglobulinemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** SNS-062

## Key facts

- **NCT ID:** NCT03037645
- **Lead sponsor:** Sunesis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-28
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the Phase 1b to advance to Phase 2.
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03037645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03037645, "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03037645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*